Merck & Co Inc

Research Merck & Co Inc (MRK) on Bullrun: valuation model: 47.8% overvalued, market cap USD 359.43B, P/E 116.4, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Merck & Co Inc as 47.8% overvalued; latest market cap is USD 359.43B; P/E is 116.4; dividend yield is 2.3%.

Peer valuation comparison

Latest P/E is 116.38x versus a Healthcare sector median of 24.61x (372.9% above).

Latest dividend yield is 2.34% versus a Healthcare sector median of 1.84% (27.2% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 65.01BUSD 18.25BUSD 12.36B74.8%7.28USD 14.57BUSD 49.34BUSD 52.61B
FY2024USD 64.17BUSD 17.12BUSD 18.10B76.3%6.74USD 13.24BUSD 37.11BUSD 46.31B
FY2023USD 60.12BUSD 365.00MUSD 9.14B73.2%0.14USD 6.84BUSD 35.06BUSD 37.58B
FY2022USD 59.28BUSD 14.52BUSD 14.71B70.6%5.71USD 12.69BUSD 30.69BUSD 45.99B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-09USD 359.43B116.42.3%3.4
20252025-12-31USD 260.48B14.53.1%3.28
20242024-12-31USD 251.45B14.83.1%3.12
20232023-12-29USD 276.26B60.62.7%2.96
20222022-12-30USD 281.30B18.52.5%2.8
20212021-12-31USD 193.72B14.93.4%2.61

Dividend history

Latest trailing dividend snapshot: annual dividend/share 3.4 USD, yield 2.3%.

YearDividends/share
FY20253.28 USD
FY20243.12 USD
FY20232.96 USD
FY20222.8 USD

About Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

ETFs that hold Merck & Co Inc

Merck & Co Inc is one of the ten largest holdings of 76 ETFs that investors in Europe can buy. The 8 most traded of them:

ETFWeightTER
Vanguard FTSE All-World High Dividend Yield UCITS ETF USD Distributing0.83%0.29%
Vanguard FTSE All-World High Di0.83%0.29%
iShares S&P 500 Health Care Sector UCITS ETF USD (Acc)5.87%0.15%
Xtrackers MSCI World Health Care UCITS ETF 1C4.29%0.25%
State Street SPDR S&P 500 Leaders UCITS ETF1.43%0.03%
iShares Healthcare Innovation UCITS ETF USD (Acc)1.46%0.40%
State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF5.93%0.15%
iShares MSCI World Health Care Sector Advanced UCITS ETF USD Acc3.78%0.18%

Compare every fund on the same index:

FTSE All-World High Dividend ETFs MSCI World Minimum Volatility ETFs

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Abbvie Inc (ABBV) AMGEN Inc (AMGN) Biogen Inc (BIIB) Bristol-Myers Squibb Company (BMY) Gilead Sciences Inc (GILD) Johnson & Johnson (JNJ) Lilly(Eli) & Company (LLY) Mira Pharmaceuticals Inc (MIRA) Organon & Company (OGN) Pfizer Inc (PFE) Scilex Holding Company (SCLX) Agilent Technologies Inc (A)

Frequently asked questions

Is Merck & Co Inc overvalued or undervalued?

Bullrun's valuation model currently marks Merck & Co Inc as 47.8% overvalued.

What is Merck & Co Inc's market cap?

Merck & Co Inc's market capitalization is USD 359.43B.

What is Merck & Co Inc's P/E ratio?

Merck & Co Inc's price-to-earnings (P/E) ratio is 116.4.

Does Merck & Co Inc pay a dividend?

Merck & Co Inc has a dividend yield of 2.3%.

What does Merck & Co Inc do?

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.